Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia | Zendy

Andrew D. Beggs | Zendy; Jonathan James | Zendy; Germaine Caldwell | Zendy; Toby Prout | Zendy; Mark Dilworth | Zendy; Phillipe Taniere | Zendy; Tariq Iqbal | Zendy; Dion Morton | Zendy; Glenn Matthews | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia

Author(s) -

Andrew D. Beggs,

Jonathan James,

Germaine Caldwell,

Toby Prout,

Mark Dilworth,

Phillipe Taniere,

Tariq Iqbal,

Dion Morton,

Glenn Matthews

Publication year - 2018

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izy119

Subject(s) - dysplasia , medicine , ulcerative colitis , gastroenterology , dna methylation , biopsy , biomarker , field cancerization , methylation , pathology , cancer , biology , disease , genetics , gene , gene expression

Ulcerative colitis (UC) is associated with a higher background risk of dysplasia and/or neoplasia due to chronic inflammation. There exist few biomarkers for identification of patients with dysplasia, and targeted biopsies in this group of patients are inaccurate in reliably identifying dysplasia. We aimed to examine the epigenome of UC dysplasia and to identify and validate potential biomarkers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research